$60m cash, circa $90m market cap, $500m plus potential for PXS-4278A alone, Loxl2 deal pending - trial to commence soon, takeover potential, lots of upside here over the next 6-12 months.
NTI Neurotech knocked back by FDA as agency declares target condition not rare enough for special status
